30 closest matches · ranked by relevance
Healthy Japanese Children Age 2 Years Through 6 Years
Primary: Number of Participants With Solicited Symptoms Experienced From Administration of MEDI3250 — 57 subjects
Healthy Japanese Children Age 7 Years Through 18 Years
Primary: the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain) — 0; 1 Participants
Hypertension
Primary: Number of Participants Who Experienced At Least One Treatment-Emergent Adverse Event (TEAE) — 9 Participants
Feeding and Eating Disorders of Childhood
Primary: Exclusive Breastfeeding at Four Months of Age — 140; 104 Participants
Weight, Body · Diet Habit
Primary: Weight-for-Length Percentile — 44.94; 46.70; 58.69; 48.54 Percentile
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1 — 58.2; 51.3; 26.3; 20.0 Percentage of participants
Short Bowel Syndrome
Primary: Absolute Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data — -11.8; -26.2 mL/kg/day
Foetal Growth Problem · Small for Gestational Age
Primary: Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years — -2.9488; -2.9047; 1.2066; 2.0247…
Infections, Rotavirus · Rotavirus Vaccines
Primary: Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains — 14; 34 subjects
Obesity
Primary: Body Mass Index Z-score Change — -0.02; -0.08 BMI z-score change
Asthma
Primary: Number of Patients With Adverse Events (AEs). — 118; 116 Participants
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
Juvenile Rheumatoid Arthritis
Primary: Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16 — 23 Participants
Healthy Volunteers Only
Primary: Utilization of Toy — .45; .49; .50; .53 Proportion
Influenza
Primary: Number of Subjects With Haemagglutination Inhibition (HI) Antibody Concentrations Above the Cut-off Value — 28; 30 Subjects
Obesity in Children
Primary: Change in zBMI — -0.048; 0.013; 0.011 z-score — p=0.051
Feeding Behavior
Primary: Differences in Food and Beverage Intake by Energy — 1059; 1118; 977 kilocalories per day — p=<0.0001
Nutrition
Primary: Validated Food Frequency Questionnaire — 0.39; 0.35; 0.28; 0.32 Pearson correlation
Respiratory Syncytial Virus Infection
Primary: Serum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121 — 0; 59.0; 91.8 µg/mL
Obesity
Primary: Number of Participants Satisfied or Very Satisfied With Information Given to Them, as Measured by Follow up Questionnaire — 4; 2 Participants
Rhinitis
Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) — 15; 17; 32; 0 participants
Overweight and Obesity · Adiposity · Nutrient; Excess
Primary: Change in Mother's Height From Baseline (Time 1) to Time 2 — -0.00977; 0.000505 Centimeters
Iron Deficiency
Primary: The Primary Outcome is Iron Depletion, and Will be Defined as Serum Ferritin <10 mcg/L. — 64; 71; 13; 10 participants — p=0.42
Overweight · Obesity · Depression
Primary: Change of Body Mass Index (BMI) Z-score for Toddlers — 0.49; 0.50; 0.62; 0.52 z-score — p=0.555
Prader-Willi Syndrome
Primary: Change From Baseline to Month 12 in Lean Body Mass Measured by Dual-Energy X-ray Absorptiometry (DEXA): Adult Cohort — 3.09 Percentage of body mass
Pediatric Obesity
Primary: Child BMI — 98.47; 97.86; 98.19; 97.86 percentile — p=.008
Hepatitis B
Primary: Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection — 90.1; 82.5 Percentage of participants
Obesity
Primary: Beta-carotene Levels Between Overweight and Lean Boys at Baseline — 0.22; 0.29 mM/L
Educational Intervention and Toddler Bottle Use
Primary: Change in Iron Depletion — 88; 83; 12; 17 percentage of participants
Japanese Encephalitis · Measles · Mumps
Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or…